Suraksha Diagnostic Ltd. stock analysis
Want to see IN:SURAKSHA full AI Analyst Report?
Suraksha Diagnostic Ltd. (SURAKSHA) Stock Price & Analysis
SURAKSHA Stock Chart & Stats
- Day’s Range
- INR 338.70 - INR 355.00
- 52-Week Range
- INR 224.10 - INR 381.10
- Previous Close
- INR 340.65
- Volume
- N/A
- Average Volume (3M)
- 8,412
- Market Cap
- INR 17.74B
- Enterprise Value
- INR 19.88B
- Total Cash (Recent Filing)
- INR 263.48M
- Total Debt (Recent Filing)
- INR 0
- Price to Earnings (P/E)
- 42.6
- Beta
- 0.86
- Next Earnings
- Feb 13, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Sep 15, 2026
- Dividend Yield
- 0.29%
Bulls Say, Bears Say
Bulls Say
Sustained Revenue Growth
Revenue growth remained solid across three consecutive fiscal years after the FY23 contraction, indicating continued expansion in diagnostic testing demand. Sustained top-line growth can support operating scale, broaden the customer base, and provide a durable foundation for future earnings development.
Healthy Operating Profitability
Healthy operating and EBITDA margins show that Suraksha converts diagnostic service revenue into meaningful operating earnings. This profitability provides internal resources for network development and equipment investment while offering some resilience if revenue growth moderates over the next several quarters.
Strong Operating Cash Generation
Operating cash flow exceeding reported net income supports the quality of accounting earnings and demonstrates that the core business is generating cash from operations. This strengthens funding capacity for routine investment and reduces reliance on external financing to sustain operations.
Bears Say
Margin Compression And Volatility
The sharp FY26 gross-margin decline and lower net margin show that profitability has not been consistently stable despite continued revenue growth. Persistent margin pressure could reduce earnings scalability and weaken the company’s ability to convert market expansion into durable bottom-line growth.
Rising Leverage And Lower Returns
Higher leverage alongside declining return on equity indicates that incremental balance-sheet investment is currently producing lower returns. If this pattern persists, interest obligations and reduced capital efficiency could constrain financial flexibility and limit funding available for expansion.
Weak Free-Cash-Flow Conversion
Although operating cash generation is positive, converting earnings into free cash flow remains weak and uneven. Low free-cash-flow conversion may reflect substantial capital spending or working-capital needs, limiting discretionary cash available for debt reduction, shareholder returns, or growth initiatives.
Suraksha Diagnostic Ltd. News
SURAKSHA FAQ
What was Suraksha Diagnostic Ltd.’s price range in the past 12 months?
What is Suraksha Diagnostic Ltd.’s market cap?
When is Suraksha Diagnostic Ltd.’s upcoming earnings report date?
How were Suraksha Diagnostic Ltd.’s earnings last quarter?
Is Suraksha Diagnostic Ltd. overvalued?
Does Suraksha Diagnostic Ltd. pay dividends?
What is Suraksha Diagnostic Ltd.’s EPS estimate?
How many shares outstanding does Suraksha Diagnostic Ltd. have?
What happened to Suraksha Diagnostic Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Suraksha Diagnostic Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Suraksha Diagnostic Ltd.
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In addition, the company provides dental, physiotherapy, immunology & rheumatology, eye, fetal care, ENT, and speciality clinics, as well as home doctor visit services. The company was founded in 1992 and is based in Kolkata, India.
- Sector
- General
- Industry
- Medical - Care Facilities
- CEO
- Ritu Mittal
- Employees
- 1,600
- Website
- www.surakshanet.com
- Address
- Plot No. DG- 12/1, Kolkata, WB, 700156, IN
Suraksha Diagnostic Ltd. (SURAKSHA) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 5 | 4 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 10 | 0 | 2 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| IN:KRSNAAKrsnaa Diagnostics Limited | ||
| IN:LALPATHLABDr. Lal PathLabs Limited | ||
| IN:METROPOLISMetropolis Healthcare Ltd. | ||
| IN:THYROCAREThyrocare Technologies Ltd | ||
| IN:VIMTALABSVimta Labs Limited |







